Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
February 27 2025 - 9:02AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month
of February 2025
Commission File
Number: 001-41316
Alpha Tau Medical Ltd.
(Exact Name of
Registrant as Specified in Its Charter)
Kiryat HaMada St. 5
Jerusalem, Israel 9777605
+972 (3) 577-4115
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
CONTENTS
On February 27, 2025, Alpha Tau Medical Ltd. (the “Company”)
issued a press release titled “Alpha Tau to Participate in March Investor Conferences.” A copy of this press release is attached
to this Form 6-K as Exhibit 99.1.
The information in this Report on Form 6-K, including in Exhibit 99.1
attached hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed
incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except
as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Alpha Tau Medical Ltd. |
| |
|
|
| Date: February 27, 2025 |
By: |
/s/ Uzi Sofer |
| |
|
Uzi Sofer |
| |
|
Chief Executive Officer |
3
Exhibit
99.1
Alpha
Tau to Participate in March Investor Conferences
JERUSALEM,
February 27, 2025 -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer
of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that
CFO Raphi Levy will present at the following investor conferences in March 2025.
| Event: |
Investor
Summit Event |
| Format: |
Presentation |
| Date: |
March
11, 2025 |
| Time: |
12:00PM
– 12:30PM ET |
| Location: |
Virtual |
| Event: |
Oppenheimer
35th Annual Healthcare MedTech & Services Conference |
| Format: |
Presentation |
| Date: |
March
17, 2025 |
| Time: |
3:20PM
– 3:50PM ET |
| Location: |
Virtual |
| Event: |
Sidoti
Small Cap Conference |
| Format: |
Presentation |
| Date: |
March
19, 2025 |
| Time: |
11:30AM
– 12:00PM ET |
| Location: |
Virtual |
Mr. Levy will also be available for
1x1 investor meetings at the conferences. Please reach out to your Investor Summit Group, Oppenheimer, and Sidoti representatives to
schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli
oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment
of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters
Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224
impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy
alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims
to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
IR@alphatau.com
Alpha Tau Medical (NASDAQ:DRTSW)
Historical Stock Chart
From Feb 2025 to Mar 2025
Alpha Tau Medical (NASDAQ:DRTSW)
Historical Stock Chart
From Mar 2024 to Mar 2025
